Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVAR

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease

Related Keywords

Germany , Japan , United States , Canada , Switzerland , America , American , Isabella Zinck , Susanne Schaffert , Amy Wolf , Nicole Zinsli Somm , Robert Zeiser , Samir Shah , Parag Mahanti , Sloan Simpson , Alina Levchuk , American Society Of Blood , Twitter , Department Of Haematology , European Commission , Novartis External Communications , Lymphoma Society , Novartis , Exchange Commission , University Hospital Freiburg , European Medicines Agency , Staging Working Group , Committee For Medicinal Products Human Use , Novartis Hematology Communications , Medicinal Products , Human Use , Stem Cell Transplantation , New England Journal , Graft Versus Host Disease , Host Disease , Why Havent We Made More , Chronic Graft Versus Host Disease , Health Consensus Development Project , Clinical Trials , Blood Marrow , American Society , Biol Blood Marrow , Investegate Announcements , Investegate Company Announcements , Ovartis Ag Chf0 50 Regd , Lobenewswire , Lobenewswire And Globenewswire , Nw ,